Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pamela L. Mendoza-Munoz has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Design, synthesis, and structure–activity relationship studies of 4-substituted phenylpyrazolidinone derivatives as potent Ku70/80 targeted DNA-PK inhibitors

    by Narva Deshwar Kushwaha, Pamela VanderVere-Carozza, Tyler L. Vernon, Pamela L. Mendoza-Munoz, Jitender D. Gaddameedi, Karim Ben Ali Gacem, Joseph Engel, Jean-Baptiste Charbonnier, Navnath S. Gavande, John J. Turchi

    The Ku70–Ku80 (Ku) heterodimer complex plays a central role in the non-homologous end joining (NHEJ) double-strand break (DSB) repair pathway and the DNA damage response (DDR). Like DNA–PK, Ku is a promising drug target for cancer treatment when combined with radiotherapy or DSB-inducing agents. We have previously reported the first-in-class, early-generation, highly potent, and specific Ku–DNA binding inhibitors (Ku-DBi's) that block the Ku interaction with DNA and inhibit DNA-PK kinase activity. These early-generation Ku-DBi's also inhibit cellular DNA-PK, NHEJ-catalyzed DSB repair, sensitize non-small cell lung cancer (NSCLC) cells to DSB-inducing agents, and potentiate the cellular effects of these agents via p53 phosphorylation through the activation of the ATM pathway. In this study, we report a comprehensive structure–activity relationship (SAR) analysis around the initial X80 hit molecule to develop highly potent Ku-DBi's. Early generation Ku-DBi's display a potent Ku–DNA binding inhibitory activity with a range of 2 to 6 μM, and DNA-PK inhibitory activity in the nanomolar range of approximately 110 nM. Microscale thermophoresis assay shows that these compounds inhibit Ku70–Ku80 binding to DNA with a Kd value of 0.4–6.4 μM. The thermal stability analysis also supports the notion that these Ku-DBi's bind to the Ku as measured by nanoDSF (Differential Scanning Fluorimetry), which is consistent with the observed SAR trends. These Ku-DBi's may serve as candidate compounds for further modification and development as anticancer therapeutics in combination with radiotherapy or DSB-inducing agents to treat certain DNA repair-deficient cancers.


  • Open Access

    Structure-Based Design and Development of 2-Oxindole Derivatives as Next Generation Ku-DNA Binding Inhibitors (Ku-DBi’s) for Cancer Therapy.

    by Narva Deshwar Kushwaha, Dineshsinha Chauhan, Pamela L. Mendoza-Munoz, Joseph Engel, Hariprasad Aruri, Ladislau C. Kovari, John J. Turchi, Navnath S. Gavande

    The Ku70/Ku80 heterodimer (Ku) plays a key role in the non-homologous end joining (NHEJ) pathway by recognizing DNA double-strand breaks (DSBs) and recruiting DNA-PKcs to initiate DNA repair. Aberrant activation of this pathway contributes to therapy resistance in cancer by enhancing DNA repair capacity. Although DNA-PK inhibitors show strong in vitro potency, their clinical advancement has been hindered by poor selectivity, low tumor accumulation, and systemic toxicity, preventing the achievement of maximum tolerated doses. To address these limitations, we targeted the Ku-DNA interaction and were the first to develop Ku-DNA binding inhibitors (Ku-DBi’s) that block the Ku70/Ku80 interaction with DNA, thereby inhibiting DNA-PK activation and downstream repair. Our earlier Ku-DBi’s exhibited potent inhibitory activity and selectivity, but their in vivo utility was restricted by poor solubility, metabolic stability, and limited cellular permeability. In this study, we identified lead compounds with a novel 2-oxindole scaffold through iterative structure-activity relationship (SAR) optimization. This series of compounds maintained potent biochemical activity while exhibiting enhanced solubility, cellular permeability, and metabolic stability. Lead candidates 34 (GL-3395), 35 (GL-3392), 47 (GL-3367), and 53 (GL-3609) inhibited Ku-DNA binding at 1-4 µM and DNA-PK at 0.30-0.80 µM. Notably, compounds 19 (GL-3391), 35 (GL-3392), and 38 (GL-3366) exhibited significantly enhanced cellular uptake in both A549 and H460 cells under standard conditions without serum-free media. Molecular docking and in silico ADME profiling supported their favorable binding and drug-like properties. These findings offer a promising foundation for advancing Ku-DBi as an adjuvant therapy for DNA damage-based cancer treatment.

  • Open Access

    Design, Synthesis, and Structure–Activity Relationship Studies of 4-substituted Phenylpyrazolidinone Derivatives as Potent Ku70/80 Targeted DNA-PK Inhibitors

    by Narva Deshwar Kushwaha, Pamela VanderVere-Carozza, Tyler L. Vernon, Pamela L. Mendoza-Munoz, Jitender D. Gaddameedi, Karim Ben Ali Gacem, Jean-Baptiste Charbonnier, Navnath S. Gavande, John J. Turchi

    The Ku70-Ku80 (Ku) heterodimer complex plays a central role in the non-homologous end joining (NHEJ) double-strand break (DSB) repair pathway and the DNA damage response (DDR). Like DNA-PK, Ku is a promising drug target for cancer treatment when combined with radiotherapy or DSB-inducing agents. We have previously reported the first-in-class early-generation highly potent and specific Ku-DNA binding inhibitors (Ku-DBi’s) that block the Ku interaction with DNA and inhibit DNA-PK kinase activity. These early-generation Ku-DBi’s also inhibit cellular DNA-PK, NHEJ-catalyzed DSB repair, sensitize non-small cell lung cancer (NSCLC) cells to DSB-inducing agents, and potentiate the cellular effects of these agents via p53 phosphorylation through the activation of the ATM pathway. In this study, we report a comprehensive structure-activity relationship (SAR) around the initial X80 hit molecule to develop highly potent Ku-DBi’s. Early generation Ku-DBi’s display a potent Ku-DNA binding inhibitory activity with a range of 2 to 6 μM, and DNA-PK inhibitory activity in the nanomolar range of approximately 110 nM. Microscale thermophoresis assay shows that these compounds inhibit Ku70-Ku80 binding to DNA with a Kd value of 0.4-6.4 μM. The thermal stability analysis also supports the notion that these Ku-DBi’s bind to the Ku as measured by nano DSF, which is consistent with the observed SAR trends. These Ku-DBi’s may serve as candidate compounds for further modification and development as anticancer therapeutics in combination with radiotherapy or DSB-inducing agents to treat certain DNA repair-deficient cancers.

  • Open Access

    Impact of Optimized Ku–DNA Binding Inhibitors on the Cellular and In Vivo DNA Damage Response

    by Pamela L. Mendoza-Munoz, Narva Deshwar Kushwaha, Dineshsinha Chauhan, Karim Ben Ali Gacem, Joy E. Garrett, Joseph R. Dynlacht, Jean-Baptiste Charbonnier, Navnath S. Gavande, John J. Turchi

    Background: DNA-dependent protein kinase (DNA-PK) is a validated cancer therapeutic target involved in DNA damage response (DDR) and non-homologous end-joining (NHEJ) repair of DNA double-strand breaks (DSBs). Ku serves as a sensor of DSBs by binding to DNA ends and activating DNA-PK. Inhibition of DNA-PK is a common strategy to block DSB repair and improve efficacy of ionizing radiation (IR) therapy and radiomimetic drug therapies. We have previously developed Ku–DNA binding inhibitors (Ku-DBis) that block in vitro and cellular NHEJ activity, abrogate DNA-PK autophosphorylation, and potentiate cellular sensitivity to IR. Results and Conclusions: Here we report the discovery of oxindole Ku-DBis with improved cellular uptake and retained potent Ku-inhibitory activity. Variable monotherapy activity was observed in a panel of non-small cell lung cancer (NSCLC) cell lines, with ATM-null cells being the most sensitive and showing synergy with IR. BRCA1-deficient cells were resistant to single-agent treatment and antagonistic when combined with DSB-generating therapies. In vivo studies in an NSCLC xenograft model demonstrated that the Ku-DBi treatment blocked IR-dependent DNA-PKcs autophosphorylation, modulated DDR, and reduced tumor cell proliferation. This represents the first in vivo demonstration of a Ku-targeted DNA-binding inhibitor impacting IR response and highlights the potential therapeutic utility of Ku-DBis for cancer treatment.